Disease modification and prevention
In type 1 diabetes, the direction is from treating established disease toward delaying or preventing onset in identified at-risk individuals, which requires population screening for islet autoantibodies and an infrastructure to monitor those identified.
In type 2 diabetes, remission through weight reduction — surgical, dietary or pharmacological — has shifted the framing from lifelong progressive disease to a potentially reversible one, with durability the open question.
Beta-cell replacement
Stem cell-derived islet replacement is the long-standing goal, with immune protection — avoiding lifelong immunosuppression — the principal obstacle. It should be read as advancing but not established.
Precision
Type 2 diabetes is heterogeneous, and sub-classification by phenotype or genotype aims at matching treatment to subtype. Monogenic diabetes is the proof that classification changes treatment; whether the same holds across common type 2 subtypes is unresolved.
The hard constraint
The most effective recent therapies are expensive, and diabetes prevalence is rising fastest in low- and middle-income settings. Insulin access remains a problem a century after its discovery.
The gap between what is possible and what is delivered is now the dominant issue in this field, and it is a health-systems question rather than a pharmacological one.
Methodological direction
Longer follow-up for durability. Hard outcomes rather than HbA1c. Trials conducted in the populations where burden is greatest rather than only where trial infrastructure exists — a generalisability problem that currently limits what the evidence can support.
In short
What to take from this.
- Remission durability is unresolved — do not present it as established.
- Beta-cell replacement is advancing, not established.
- Trial populations do not match where disease burden is greatest.
Sources
- Established literature on type 1 diabetes prevention and screening
- Type 2 diabetes remission evidence
- Global access literature on insulin and diabetes care
This page reflects established understanding as at mid-2026 and is not a current-awareness service. Clinical and regulatory positions change; verify anything decision-relevant against a current source.
Related